Abstract 1584P
Background
The impact of TB (which contributes to both financial and time toxicities) on cancer treatment and outcomes, especially in RLS remains largely understudied. We assessed the impact of TB on the outcomes of patients with CRC treated at a regional cancer center in RLS.
Methods
All patients with newly diagnosed CRC in 2022 at the State Cancer Institute, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, North India were enrolled. TB was recorded as the average time required to traverse the shortest distance between the cancer center and the place of the patient’s residence.
Results
263 patients (42.6% females) with CRC were included, including patients who travelled from their homes (group A) and those who rented apartments near the hospital to complete treatment (group B). Group A patients (N=178) travelled 22 km (48 mins) [median] to reach the cancer center while Group B patients (N=85) resided 75 km (130 mins) [median] away from the hospital. Travel time did not correlate with symptom duration prior to diagnosis of CRC. In group A, patients with highest TB (Q4 travel time) had poorer outcomes than other patients (Q1-Q3 of travel time) (18-month OS of 65% v 83.6%, adjusted HR 2.5 [95% CI 1.2 to 5.2]) (Table). 18-month OS in group B was higher than that for group A patients (85.6% v 78.9%, p=0.056). Table: 1584P
Predictors of OS in patients with CRC [data expressed as HR (95% CI), p-value]
| Parameter | Group A | Group B | ||
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |
| 1. Age ≥50 years | 1.6 (0.8 to 3.5), 0.2 | 1.3 (0.3 to 6.4), 0.8 | ||
| 2. Female sex | 0.8 (0.4 to 1.5), 0.4 | 0.5 (0.1 to 2.3), 0.3 | ||
| 3. Presence of comorbidity | 1.1 (0.5 to 2.1), 0.8 | 0.0 (0.0 to 8.0), 0.2 | ||
| 4. ECOG >1 | 3.6 (1.7 to 7.5), 0.001 | 3.4 (1.4 to 7.9), 0.005 | 0.8 (0.1 to 6.7), 0.9 | |
| 5. Left vs right colon | 1.3 (0.5 to 3.5), 0.6 | 1.6 (0.12 to 13.4), 0.7 | ||
| 6. Metastatic disease | 8.1 (4.0 to 16.2), ConclusionsOur study demonstrates that TB is significantly associated with poorer outcomes in patients with CRC. Clinical trial identificationEditorial acknowledgementLegal entity responsible for the studyS.Z. Banday. FundingHas not received any funding. DisclosureB. Gyawali: Financial Interests, Personal, Writing Engagement, For writing Medscape Columns: Medscape; Financial Interests, Personal, Invited Speaker, For giving invited talks and grand rounds at universities, cancer centers and professional societies: Various academic and professional organizations; Financial Interests, Personal, Other, Consulting services: Vivio Health; Non-Financial Interests, Member: ASCO, IASLC, JSMO. All other authors have declared no conflicts of interest. Resources from the same session1199P - Developing and systematically validating homologous recombination repair gene detection method based on next-generation sequencingPresenter: Yi Sun Session: Poster session 10 1200P - Investigation of multiphoton microscopy as an innovative tool for intraoperative section-free histologic investigations in just a few minutesPresenter: Martí Homs Soler Session: Poster session 10 1201P - Novel deep learning model and validation of whole slide images in lung cancer diagnosisPresenter: Alhassan Ahmed Session: Poster session 10 Resources: Abstract 1202P - A deep learning approach using routine pathology images to guide precision medicine in metastatic CRCPresenter: Chaitanya Parmar Session: Poster session 10 1203P - Analytical evaluation of whole genome sequencing for acute myeloid leukemiaPresenter: Guidantonio Malagoli Tagliazucchi Session: Poster session 10 1204P - Real-world utility of whole genome sequencing for patients with cancer: Evaluation of a regional implementation of the 100,000 genomes projectPresenter: Helen Robbins Session: Poster session 10 1205P - A retrospective machine learning-based analysis of nationwide cancer CGP data across cancer types to identify features associated with recommendation of mutation-based therapyPresenter: Hiroaki Ikushima Session: Poster session 10 1478P - Dual single-nucleotide polymorphism biomarker combination to select opioid for cancer pain managementPresenter: Yoshihiko Fujita Session: Poster session 10 1479P - Use of rescue opioids and pain control after ketamine initiation in refractory cancer pain: A multicentric observational studyPresenter: Pablo Gallardo Melo Session: Poster session 10 1480P - Long term therapy with denosumab and zoledronic acid: A comparative real-world retrospective observational study on skeletal-related events and pain in patients with metastatic breast cancerPresenter: Giacomo Massa Session: Poster session 10 This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
| |||